

Millennium Pharmaceuticals to Acquire COR Therapeutics in \$2.0 Billion Deal

2001-12-07

On December 6, 2001, Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) announced that it had signed a definitive agreement to acquire COR Therapeutics, Inc. (Nasdaq: CORR) in a stock-for-stock exchange valued at \$2.0 billion.

Millennium was advised by the following Hale and Dorr lawyers:

- on corporate and securities matters, partners David Redlick, [Jeff Stein](#) and [Jonathan Wolfman](#), junior partner Ken Lepage and associate Kris Spreen;
- on intellectual property and licensing matters, partner Steven Singer, junior partner Michael Twomey and associates Jan Siok and Soojin Chung;
- on tax matters, partner Rob Burke and associate Erika Buell;
- on real estate matters, partner Keith Barnett;
- on environmental matters, partner [Rob Kirsch](#) and associate Pat van der Voorn;
- on employee benefits matters, partner Bill Schmidt; and
- on immigration matters, partner Carolyn Fuchs.